Content about John Lechleiter

January 29, 2013
Eli Lilly reports 1% Q4 decline from Zyprexa patent expiration

Eli Lilly and Company reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

April 13, 2012
Lilly chief executive John Lechleiter appointed as PhRMA chairman

The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting.

BOSTON — The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting. The group also elected Celgene president and CEO Robert Hugin as chairman-elect of its board of directors and Pfizer president and CEO Ian Read as board treasurer. Lechleiter replaces Sanofi CEO Christopher Viehbacher as chairman.

March 9, 2011
Lilly head continues call for medical innovation

Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately. On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

TOKYO — Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately.

On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

February 10, 2011
Lilly chief calls on industry, public policy to support innovation

Public policies to support medical innovation will help drug companies address diseases that devastate people’s lives, a drug company executive said at a summit Thursday.

LONDON — Public policies to support medical innovation will help drug companies address diseases that devastate people’s lives, a drug company executive said at a summit Thursday.

Speaking at The Economist magazine’s 2011 Pharma Summit, Eli Lilly chairman, president and CEO John Lechleiter called for a new approach to research in such illnesses as Alzheimer’s disease, diabetes and cancer. This included changing the way companies conduct research and public policies that promote an environment in which innovation can flourish.

November 2, 2010
Lilly CEO: 'New approaches' must be found to combat diabetes

The CEO of drug maker Eli Lilly has called for a “wave of invention” to...

CLEVELAND The CEO of drug maker Eli Lilly has called for a “wave of invention” to combat diabetes.

Speaking at the Cleveland Clinic Medical Innovation Summit, John Lechleiter said breakthroughs against the disease are needed as urgently today as a century ago, noting that the disease could create a “health and economic time bomb,” as 1-in-3 Americans are forecasted to have the disease by 2050.

 

January 14, 2010
Innovation key to future prosperity and health, Lilly chief says

Sustaining the country’s edge in innovation and improving focus on people in medical innovations will...